Commentary: APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort

Affiliations

Comment

Kyle Kasparian et al. Front Immunol. 2020.

. 2020 Sep 15:11:1939.

doi: 10.3389/fimmu.2020.01939. eCollection 2020.

No abstract available

Keywords: APOE; APOE and COVID-19; APOE and SARS-CoV-2; APOE and inflammation; APOE e4; APOE e4 and COVID-19; APOE e4 and inflammation; COVID-19.

Comment on

APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort.
Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D. Kuo CL, et al. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2232. doi: 10.1093/gerona/glaa131. J Gerontol A Biol Sci Med Sci. 2020. PMID: 32451547 Free PMC article. No abstract available.

1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620–9. 10.1172/JCI137244 - DOI - PMC - PubMed
1. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev. (2011) 243:152–62. 10.1111/j.1600-065X.2011.01043.x - DOI - PMC - PubMed
1. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. (2020) 33:373–4. 10.1093/ajh/hpaa057 - DOI - PMC - PubMed
1. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. (2020) 3:e205619. 10.1001/jamanetworkopen.2020.5619 - DOI - PMC - PubMed
1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. . Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. medRxiv. (2020) 2020.2004.2023.20076042. 10.1101/2020.04.23.20076042 - DOI - PMC - PubMed